Henlius - Model HLX22 - Humanised IgG1 Monoclonal Antibody Injection

HLX22,  humanised IgG1 monoclonal antibody injection targeting human epidermal growth factor receptor-2 (HER2). First patient has been dosed in Phase 2 clinical trial to compare HLX22 in combination with trastuzumab and chemotherapy as first-line therapy for HER2-positive locally advanced or metastatic gastric cancer patients in Chinese mainland.